Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers: Results from a phase II basket trial

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.06.19
Views: 979

Prof Bob Li - Memorial Sloan Kettering Cancer Center, New York City, USA

Prof Bob Li talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase II trial that examined the clinical activity of ado-trastuzumab emtansine in patients with HER2-amplified salivary gland cancer.

He reports that a 90 percent response rate was achieved in these patients. Overall, The drug also demonstrated a durable efficacy and was well-tolerated. Biomarkers for HER2-amplification were also well correlated with FISH and immunohistochemistry.

Prof Li mentions that further work will focus on improving the biomarkers, which includes looking into cell-free DNA, acquired resistance mechanisms and dimerisation assays.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation